Developing a single-dose, intranasal, live-attenuated vaccine against COVID-19
Codagenix is a clinical stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. For cancer, our nimble platform allows us to turn a virus into a potential oncolytic immuno-oncology therapies. Both programs rely on scalable, low-cost manufacturing.
The COVID-19 pandemic continues to spread in the U.S. and around the world. COVI-VAC is a single-dose, intranasal, live attenuated vaccine against COVID-19, generated using Codagenix’s proprietary deoptimization technology.
Target customized oncolytics to treat primary tumors and shrink off-site metastases
177,000
RSV hospitalizations among adults 65+ no vaccine
48.8 million
Flu cases in 2017-18, current vaccines <37% effective
1 in 8
US women (about 12%) will develop invasive breast cancer during lifetime.
Our breakthrough approach to live-attenuated virus design
1. Recode
2. Synthesize
3. Transfect
4. Recover
-
June 30, 2021
Intranasal COVID-19 vaccine demonstrates single-dose efficacy in preclinical studies, in parallel with achievement of Phase 1 clinical milestone
-
June 09, 2021
Intranasal vaccines aim to stop COVID-19 where it starts